Table 2.

HDACi applied in animal models of renal fibrosis

HDACi	Specificity	Animal model	Reference
TSA	Class I/II	STZ-induced diabetic kidney	[39]
		UUO model	[36, 39, 46, 55, 68]
		Doxorubicin-induced nephropathy	[35]
		IRI-induced fibrosis	[34]
		Adenine CKD model	[35]
VPA	Class I	UUO model	[38]
		Doxorubicin-induced nephropathy	[38]
		STZ-induced diabetic kidneys	[39, 48]
MS-275	Class I	UUO model	[37]
		IRI-induced fibrosis	[34]
NaB	Pan-HDACi	STZ-induced diabetic kidney	[32, 49]
SAHA	Class I/II	STZ-induced diabetic kidney	[33, 66]
SB939	Pan-HDACi	UUO model	[54]
Tubastatin A	HDAC6	Angiotensin II-infused mice	[41]

HDACs, histone deacetylases; TSA, trichostatin A; VPA, valproic acid; SAHA, suberoylanilide hydroxamic acid; HDACi, HDAC inhibitor; UUO, unilateral ureteral obstruction.